TY - JOUR
T1 - Fluticasone propionate/formoterol
T2 - A fixed-combination therapy with flexible dosage
AU - Papi, A.
AU - Blasi, F.
AU - Canonica, G. W.
AU - Cazzola, M.
AU - Centanni, S.
AU - Foschino Barbaro, M. P.
AU - Melani, A. S.
AU - Paggiaro, P.
AU - Ricciardolo, F.
AU - Rossi, A.
AU - Scichilone, N.
N1 - Funding Information:
–F. Blasi served as advisory board member or received lectures honoraria or research grants from AstraZeneca, Almirall, Bayer, Boehringer Ingelheim, Chiesi, Dompè, GSK, Guidotti-Malesci, Menarini, Mundipharma, Novartis, and Zambon.
Funding Information:
–M. Cazzola has received honoraria for speaking and consulting and/or financial support for attending meetings from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Dey, GlaxoSmithKline, Lallemand, Menarini Farmaceutici , Mundipharma, Novartis, Pfizer , Sigma Tau , and Takeda .
Publisher Copyright:
© 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - International guidelines describe asthma control as the main outcome of asthmamanagement. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2- agonists, bymeans of a single inhaler, greatly improves themanagement of the disease. The results of 9multicenter phase III clinical studies demonstrate that the fixed combination of fluticasone propionate/formoterol in a single inhaler is effective in terms of lung function and symptom control. These studies highlight the dose flexibility, safety and tolerability of this new inhaled combination. These characteristicsmeet the recommendations of nternational guidelines, and the preferences of respiratory physicianswho identified these aspects as critical components of a successful asthma therapy. Combination of fluticasone propionate/formoterol in a single inhaler provides potent anti-inflammatory activity of fluticasone propionate and rapid onset of action of the β2-agonist formoterol making this association a viable treatment option both in terms of effectiveness and compliance.
AB - International guidelines describe asthma control as the main outcome of asthmamanagement. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2- agonists, bymeans of a single inhaler, greatly improves themanagement of the disease. The results of 9multicenter phase III clinical studies demonstrate that the fixed combination of fluticasone propionate/formoterol in a single inhaler is effective in terms of lung function and symptom control. These studies highlight the dose flexibility, safety and tolerability of this new inhaled combination. These characteristicsmeet the recommendations of nternational guidelines, and the preferences of respiratory physicianswho identified these aspects as critical components of a successful asthma therapy. Combination of fluticasone propionate/formoterol in a single inhaler provides potent anti-inflammatory activity of fluticasone propionate and rapid onset of action of the β2-agonist formoterol making this association a viable treatment option both in terms of effectiveness and compliance.
KW - Asthma control
KW - Asthma exacerbations
KW - Fixed-combination therapy
KW - Fluticasone propionate/formoterol
KW - Single-aerosol inhaler
UR - http://www.scopus.com/inward/record.url?scp=84908173011&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908173011&partnerID=8YFLogxK
U2 - 10.1016/j.ejim.2014.06.022
DO - 10.1016/j.ejim.2014.06.022
M3 - Review article
C2 - 25051902
AN - SCOPUS:84908173011
VL - 25
SP - 695
EP - 700
JO - European Journal of Internal Medicine
JF - European Journal of Internal Medicine
SN - 0953-6205
IS - 8
ER -